Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 1, p. s18, 2021. DOI: 10.25251/skin.5.supp.18. Disponível em: https://skin.dermsquared.com/skin/article/view/1171. Acesso em: 19 apr. 2025.